Important Announcement Dear readers, We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we ...

The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2.

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per ...